CRO Emmes Acquires Casimir, Expanding Its Rare Disease Services
March 17, 2022
Global clinical research organization Emmes has acquired Casimir, a U.S.-based CRO that has experience in more than 20 rare diseases and has worked with regulators, sponsors, and patients to develop outcome measures that capture the nuances of disease progression and treatment benefit.
“This is the fourth acquisition for Emmes in just over a year, as we continue to add new biopharma clients and deepen our innovative research capabilities,” said Christine Dingivan, CEO of Emmes. “The combination of Casimir and Emmes will further differentiate our global rare disease center of excellence, Orphan Reach. We plan to continue and accelerate the work of Casimir in neurodegenerative and neuromuscular conditions with remote data capture and patient outcome standardization.”
Founded in 2016, Casimir is supporting 39 projects with 25 different clients. It is known for its virtual clinical trials and remote assessments that minimize the burden on patients and caregivers, especially for its efforts in Duchenne muscular dystrophy and the application of its proprietary Duchenne Video Assessment (DVA) tool that measures clinical outcomes via remote data capture. The DVA is actively being explored in a variety of other rare disease indications, as well as in other neurogenerative/ neuromuscular diseases.
“The size and reach of Emmes will give us an even greater ability to expand our current platform and outcomes development expertise to other neurodegenerative diseases and therapeutic areas,” said Christine McSherry, co-founder and CEO of Casimir.
Emmes says rare disease research is a strategic priority for the company, which established Orphan Reach. Emmes’ Rare Disease Center to combine its expertise in biostatistics, data management, and clinical research with Orphan Reach’s rare disease patient-centric focus. The acquisition of Casimir and its proprietary clinical outcomes technology will strengthen Emmes’ leadership in rare and orphan disease clinical research and drug development.
“The combination of Emmes and Casimir will provide our clients access to full-service protocol design, strategy and trial execution services, not only for rare diseases, such as DMD, but also for a variety of myopathies and neurological conditions,” said Rhonda Henry, president of Emmes’ BioPharma Group.
Author: Rare Daily Staff
Sign up for updates straight to your inbox.